Manojkumar Bupathi

Oncology

10103 RidgeGate Pkwy
Ste G23
Lone Tree, CO 80124

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Evolving treatment patterns and outcomes among patients with metastatic urothelial carcinoma post-avelumab maintenance approval: insights from The US Oncology Network.

Evolving treatment patterns and outcomes among patients with metastatic urothelial carcinoma post-avelumab maintenance approval: insights from The US Oncology Network.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.

Journal: Future oncology (London, England)

Published: September 01, 2025

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.

Journal: Urologic oncology

Published: August 21, 2025

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies.

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies.

Journal: Cancers

Published: February 07, 2025

Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study.

Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study.

Journal: Current oncology (Toronto, Ont.)

Published: December 19, 2024

Managing patients with metastatic hormone-sensitive prostate cancer: a shared-care approach to combination therapy.

Managing patients with metastatic hormone-sensitive prostate cancer: a shared-care approach to combination therapy.

Journal: Clinical advances in hematology & oncology : H&O

Published: November 07, 2024

A shared-care approach to the management of patients with mHSPC: the oncology perspective.

A shared-care approach to the management of patients with mHSPC: the oncology perspective.

Journal: Clinical advances in hematology & oncology : H&O

Published: November 07, 2024

The importance of the shared-care approach when triplet therapy is selected in mHSPC: Q&A.

The importance of the shared-care approach when triplet therapy is selected in mHSPC: Q&A.

Journal: Clinical advances in hematology & oncology : H&O

Published: November 07, 2024

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 26, 2024

Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CT.

Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CT.

Journal: Journal of clinical medicine

Published: August 22, 2024

A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.

A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.

Journal: Future oncology (London, England)

Published: April 29, 2024

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 23, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026